Lanreotid Pharmathen

Lanreotide, the active ingredient in Lanreotid Pharmathen, is a somatostatin analog presented as a subcutaneous formulation for injection use. It is employed to control hormone‑driven tumor growth and related symptoms in patients with acromegaly, gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome.

GNH USA supplies Lanreotid Pharmathen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Lanreotide is used in endocrine‑related disorders where excess hormone secretion drives disease progression.

- Acromegaly: reduces excess growth hormone levels and alleviates associated clinical features. - Gastroenteropancreatic neuroendocrine tumors (NETs): inhibits tumor growth and hormone secretion, improving disease control. - Carcinoid syndrome: lessens flushing and diarrhea by suppressing serotonin and other vasoactive peptide release.

Lanreotide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain or erythema. - Diarrhea or abdominal discomfort. - Nausea or vomiting. - Hyperglycemia or altered glucose tolerance.

Serious or Rare Side Effects: - Gallbladder disease, including cholelithiasis. - Acute pancreatitis. - Severe hypersensitivity reactions such as anaphylaxis.

When prescribing Lanreotide, clinicians should consider several safety measures.

- Monitor glucose: assess blood glucose regularly, especially in diabetic patients. - Evaluate gallbladder: perform imaging if patients develop right‑upper‑quadrant pain. - Assess pancreatic function: watch for signs of pancreatitis. - Review concomitant hormone therapies: adjust doses of insulin or oral hypoglycemics as needed. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Cyclosporine: may increase lanreotide concentrations, raising toxicity risk. - Other somatostatin analogs: additive hormonal suppression can lead to severe hypoglycemia. - Insulin or sulfonylureas: heightened risk of hyperglycemia.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in hormonal effectiveness. - Warfarin: monitor INR as lanreotide may alter anticoagulant response. - Digoxin: observe for changes in serum levels and cardiac effects.